GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
GSK could still cause problems for the British firm: UBS. GlaxoSmithKline (GSK) saw its shares jump more than 6% after the ...
Pharmaceutical company GSK agrees to pay $2.3 bn in US settlements alleging Zantac cancer claims
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...
GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits
GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...
UK firm GSK to pay $2.2bn over Zantac cancer claims
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...
GSK's Zantac settlement should give stock a boost, says Jefferies
GSK's $2.2bn payment to settle 93% of outstanding Zantac lawsuits in the US was close to the "best case scenario", according ...
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court ...
GSK surges 6.5% after $2.2 billion Zantac lawsuits settlement
The agreement, announced on Wednesday, was far lower than some analyst estimates, including JP Morgan's projection of $3.5 ...
GSK shares jump after landmark £1.68bn heartburn drug settlement
The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor ...
GSK settles vast majority of Zantac claims for $2.2 billion
The settlement will see GSK resolve around 80,000 of the Zantac claims it faces for sums well below the $30 billion worst-case scenario figure currently priced into GSK's share price, Shore Capital ...
GSK Shares Gain Over 5% At LSE After Reaching $2.2 Billion Settlement Over Heartburn Medicine Zantac
In fact, the company shares have seen a cumulative rise of 5.39 per cent or GBP 78.50. On Thursday, the green streak ...
GSK strikes £1.7bn deal over Zantac cancer claims
Pharmaceutical giant GSK will pay up to £1.7billion to settle thousands of legal cases that claimed its heartburn drug Zantac ...
GSK shares leap after drug firm settles US Zantac cancer claim lawsuit
GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...